What's Happening?
SK bioscience has announced a funding agreement with the RIGHT Foundation to support the early clinical development of its RSV preventive monoclonal antibody candidate, RSM01. The company secured approximately USD 3.0 million to accelerate the Phase 1b
clinical trial of RSM01 in infants. This candidate, licensed from the Gates Medical Research Institute, aims to provide continuous protection against RSV with a single administration. SK bioscience plans to maximize commercial value in advanced markets while supplying affordable doses to lower-income countries. The global RSV preventive antibody market is projected to reach USD 4.5 billion by 2032.
Why It's Important?
The funding agreement highlights the potential of RSM01 to address unmet medical needs in both high-income and lower-income countries. RSV is a major cause of severe respiratory infections in infants, leading to significant healthcare burdens. By advancing RSM01, SK bioscience aims to provide a more effective and accessible preventive solution. The company's strategy to integrate R&D, manufacturing, and supply underscores its commitment to global public health and competitiveness in the vaccine market.
What's Next?
SK bioscience will proceed with the Phase 1b clinical trial of RSM01, focusing on infants. The company plans to leverage its R&D and manufacturing capabilities to develop a globally competitive product. Additionally, SK bioscience is expanding its infectious disease pipeline, including next-generation vaccines, to strengthen its growth foundation and address global health challenges.
